D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

A D.C. drugmaker is fighting the FDA on multiple fronts, from trying protect its intellectual property from generic competition to battles over getting more drugs to market.

H.C. Wainwright maintained a Buy rating on Vanda Pharmaceuticals (NASDAQ:VNDA) with a price target of $18.00, representing significant upside potential from the current price of $4.31. According to ...

Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the ...

Vanda Pharmaceuticals stock opened at $4.69 on Wednesday. Vanda Pharmaceuticals has a 1-year low of $3.61 and a 1-year high of $6.75. The firm has a market capitalization of $273.47 million, a PE ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $18.0, a ...

Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Vanda (VNDA – Research Report) and keeping the price target at ...

Vanda Pharmaceuticals Inc. recently made a significant move by filing a new drug application for Tradipitant. The application, targeted at addressing motion sickness, was publicized through a social ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program.